Synta Pharmaceuticals Announces Launch Of GANNET53, A Randomized, pan-European Study Of Ganetespib In p53 Mutant, Metastatic Ovarian Cancer

Published: Jan 10, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the launch of GANNET53, a pan-European randomized trial evaluating the combination of ganetespib and paclitaxel vs. paclitaxel alone in over 200 patients with metastatic, predominantly p53 mutant, platinum-resistant ovarian cancer. Centers in Austria, Belgium, France, and Germany will participate in the clinical trial, which is expected to begin enrollment in mid-2014. Ganetespib, Synta’s lead anti-cancer drug candidate, inhibits the heat shock protein 90 (Hsp90) chaperone protein and is being studied in over 25 clinical trials, including an ongoing Phase 3 trial in advanced non-small cell lung cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news